Press Releases

August 17, 2023
Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins
August 8, 2023
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress
August 3, 2023
Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023
August 1, 2023
Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital
June 8, 2023
Revolution Medicines to Participate in Upcoming Investor Conferences
May 24, 2023
Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit
May 8, 2023
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
May 1, 2023
Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023
April 13, 2023
Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference
April 6, 2023
Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023